Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Arm Holdings plc (ARM) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

Arm Holdings plcTrade
Ginkgo Bioworks Holdings IncTrade

Price performance (Past 24H)

Key statistics

Arm Holdings plc vs Ginkgo Bioworks Holdings Inc — how do they compare? Arm Holdings plc trades at $270.94 (market cap $286.06B), while Ginkgo Bioworks Holdings Inc trades at $7.54 (market cap $515.15M). The key difference: Arm Holdings plc is far larger — about 555.3× Ginkgo Bioworks Holdings Inc's market cap, and Arm Holdings plc is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.

ARMDNA
Market Cap
$286.06B$515.15M
Sector
TechnologyHealth
52-Week High
$439.46$16.14
52-Week Low
$104.55$5.48
Enterprise Value
$282.64B$617.10M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Arm Holdings plc

ARM stock trades at $282.57, down 1.43% over 24 hours, with a bullish technical outlook supported by moving averages and key support at $272. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.45 beating the $0.40 estimate. Revenue grew to $4.01B in 2025, with a net income margin of 20.25%, though valuation multiples remain elevated with a P/E of 273.32.

The outlook is positive due to AI-driven growth in licensing and royalties, with management targeting $25B revenue by FY31. However, risks include stretched valuation, smartphone market headwinds, and execution challenges. Analyst consensus is bullish with a $329.80 price target, suggesting 17% upside from current levels.

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.97, down 6.24% today, reflecting ongoing operational challenges. The company reported Q2 2026 revenue of $20 million, a 48% year-over-year decline, as it shifts focus to autonomous lab systems. Despite beating EPS expectations in two of the last three quarters, net losses remain substantial with a -219.6% margin. Technical indicators show bearish momentum with support at $7 and resistance at $9.

DNA faces significant headwinds with declining revenue and persistent losses, though analyst sentiment is mixed with 45% buy ratings. The pivot to new business lines creates uncertainty, while cash burn and competitive pressures present substantial risks. Upside depends on successful execution of the strategic shift and path to profitability.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Arm Holdings plc

Arm Holdings designs the architecture for high-performance, energy-efficient processors used in nearly all smartphones and millions of other devices. Its intellectual property powers global computing from mobile to AI.

Read more on ARM

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA